Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

医学 彭布罗利珠单抗 耐受性 内科学 实体瘤疗效评价标准 肿瘤科 头颈部鳞状细胞癌 临床研究阶段 人口 不利影响 头颈部癌 临床试验 外科 癌症 免疫疗法 环境卫生
作者
Tanguy Y. Seiwert,Barbara Burtness,Ranee Mehra,Jared Weiss,Raanan Berger,Joseph P. Eder,Karl Heath,Terrill K. McClanahan,Jared Lunceford,Christine K. Gause,Jonathan D. Cheng,Laura Q.M. Chow
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:17 (7): 956-965 被引量:1588
标识
DOI:10.1016/s1470-2045(16)30066-3
摘要

Summary

Background

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options. We aimed to assess the safety, tolerability, and antitumour activity of pembrolizumab, a humanised anti-programmed death receptor 1 (PD-1) antibody, in patients with PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck.

Methods

This study was an open-label, multicentre, phase 1b trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients were eligible for enrolment if they were aged 18 years or older, had a confirmed diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck, and had any level of PD-L1 expression (ie, at least 1% of tumour cells or stroma that were PD-L1-positive by immunohistochemistry). Patients received pembrolizumab 10 mg/kg intravenously every 2 weeks. Primary outcomes were safety in the per-protocol population and the proportion of patients with centrally reviewed overall response per Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1). Overall response was analysed in the full analysis set, which was defined as all patients who had received at least one dose of pembrolizumab, had measurable disease at baseline, and one post-baseline scan or patients without a post-baseline scan who discontinued therapy because of disease progression or a drug-related adverse event. The study is registered with ClinicalTrials.gov, number NCT01848834 and is ongoing, but no longer enrolling patients.

Findings

Of the 104 patients screened between June 7, 2013, and Oct 3, 2013, 81 (78%) were PD-L1-positive. Of these, 60 patients with PD-L1-positive squamous cell carcinoma of the head and neck were enrolled and treated: 23 (38%) were HPV-positive and 37 (62%) were HPV-negative. Pembrolizumab was well tolerated, with 10 (17%) of 60 patients having grade 3–4 drug-related adverse events, the most common of which were increases in alanine aminotransferase and in aspartate aminotransferase, and hyponatraemia, each occurring in two of 60 patients; one patient developed a grade 3 drug-related rash. 27 (45%) of 60 patients experienced a serious adverse event. There were no drug-related deaths. The proportion of patients with an overall response by central imaging review was 18% (eight of 45 patients; 95% CI 8–32) in all patients and was 25% (four of 16 patients; 7–52) in HPV-positive patients and 14% (four of 29 patients; 4–32) in HPV-negative patients.

Interpretation

Pembrolizumab was well tolerated and demonstrated clinically meaningful antitumour activity in recurrent or metastatic squamous cell carcinoma of the head and neck, supporting further study of pembrolizumab as anticancer therapy for advanced head and neck cancers.

Funding

Merck & Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
独特的大有完成签到 ,获得积分10
刚刚
量子星尘发布了新的文献求助10
1秒前
3秒前
xingyi完成签到,获得积分10
5秒前
6秒前
舒心的秋荷完成签到 ,获得积分10
9秒前
zz123发布了新的文献求助10
10秒前
liaomr完成签到 ,获得积分10
10秒前
粗犷的灵松完成签到,获得积分10
11秒前
吃小孩的妖怪完成签到 ,获得积分10
11秒前
ncuwzq完成签到,获得积分10
13秒前
yshj完成签到 ,获得积分10
14秒前
16秒前
净禅完成签到 ,获得积分10
18秒前
20秒前
迷人的寒风完成签到,获得积分10
21秒前
21秒前
water应助科研通管家采纳,获得10
22秒前
Lucas应助HHHAN采纳,获得10
24秒前
无情修杰完成签到 ,获得积分10
25秒前
小柒完成签到 ,获得积分10
27秒前
聪慧芷巧发布了新的文献求助10
28秒前
29秒前
33秒前
蓝意完成签到,获得积分0
34秒前
xiaohongmao完成签到,获得积分10
39秒前
42秒前
qweerrtt完成签到,获得积分10
49秒前
49秒前
与共发布了新的文献求助10
50秒前
carly完成签到 ,获得积分10
51秒前
颢懿完成签到 ,获得积分10
54秒前
量子星尘发布了新的文献求助10
55秒前
57秒前
ljc完成签到 ,获得积分10
58秒前
Java完成签到,获得积分10
1分钟前
1分钟前
鲤鱼安青完成签到 ,获得积分10
1分钟前
1分钟前
dollarpuff完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022